Skip to content
Fliar PrismExplore
Disease explorerOpen Prism

Type 2 diabetes

One condition, every record we hold on it: what the evidence supports, what people living with it actually ask, what the news follows, what is being patented, what companies are building, what those businesses earn, and what people install on their phones.

Trace type 2 diabetes across Prism's evidence, research, news, patent, community, company and filing records — the graph behind its causes and treatments, what patients ask and pay, what startups are building, and what those businesses actually earn.

Open the evidence graph Explore the geography
How the condition develops
insulin signalPancreasMuscle & liverPancreasMuscle & liverPancreasMuscle & liver
Normal handling: the pancreas releases insulin, and muscle and liver take glucose out of the blood in response.
The evidence snapshot

Related records across every corpus we hold, not a severity score.

182,350extracted claims · 23,949 high-strength
128,367research records · through 2025
87,528news matches · May 2021–Apr 2026
49,718patent publications · through 2024
1,260companies classified to the field

Built 2026-09-18 · Measurement windows and limitations

The evidence graph

182,350 extracted claims link type 2 diabetes to 85,361 distinct factors. The graph below ranks them by evidence strength rather than by how often each is written about — for this subject, and for most, those are different answers.

Prism claim record
Size by

Sized by claims at high or very high evidence strength. A dashed ring marks a link whose claims since 2023 outnumber 2019–2022 by more than two to one.

Causes & risk factorstop 10 by evidence
  1. obesity146 strong / 3,971
  2. overweight55 strong / 1,160
  3. age32 strong / 301
  4. smoking31 strong / 252
  5. insulin resistance24 strong / 768
  6. physical inactivity23 strong / 203
  7. obese18 strong / 295
  8. body mass index17 strong / 57
  9. family history16 strong / 195
  10. gestational diabetes15 strong / 265
Treatmentstop 10 by evidence
  1. metformin334 strong / 1,642
  2. liraglutide165 strong / 402
  3. semaglutide ↑163 strong / 695
  4. tirzepatide ↑162 strong / 487
  5. dapagliflozin117 strong / 250
  6. sitagliptin106 strong / 236
  7. insulin glargine90 strong / 134
  8. sglt2 inhibitors80 strong / 303
  9. basal insulin72 strong / 167
  10. exercise68 strong / 521
Protective factorstop 10 by evidence
  1. mediterranean diet ↑29 strong / 201
  2. coffee28 strong / 200
  3. weight loss20 strong / 166
  4. physical activity19 strong / 250
  5. whole grains17 strong / 149
  6. exercise11 strong / 274
  7. healthy diet10 strong / 244
  8. diet9 strong / 190
  9. healthy lifestyle8 strong / 129
  10. drinking coffee8 strong / 87
Mechanismstop 8 by evidence
  1. insulin resistance10 strong / 187
  2. inflammation7 strong / 64
  3. insulin5 strong / 99
  4. gut microbiota4 strong / 20
  5. sglt2i4 strong / 7
  6. elevated blood sugar levels3 strong / 4
  7. sitagliptin3 strong / 3
  8. metformin2 strong / 17

Written about most, supported least

Links with the widest gap between how often they are claimed and how often a strong study carries the claim.

Linked termClaimsHigh-strengthShare
lack of exercise1600none
intermittent fasting860none
ozempic1,249141.1%
sedentary lifestyle20731.4%
poor diet21941.8%
high blood pressure14932.0%

What kind of study the claims come from

Every source document classified by design.

49%8%26%10%
Unspecified — 90,068 (49.4%)Preclinical — 14,986 (8.2%)Clinical & observational — 48,147 (26.4%)Review & meta-analysis — 17,427 (9.6%)Randomised trial — 11,722 (6.4%)

Every node here is a live subject in the disease evidence explorer: selecting one opens it as the centre of its own graph, with every other condition it touches.

Research landscape

128,367 research records carry this condition as an indexed subject heading between 2012 and 2025 — 10,214 of them randomised trials and 5,032 meta-analyses. The mix matters more than the total: it is what the evidence strengths in the graph above are built from.

Prism research record

Research records per year

Indexed research records, 2012–2025.

03,2886,5779,86513,1532012: 6,963 All records2013: 7,374 All records2014: 7,804 All records2015: 7,904 All records2016: 8,148 All records2017: 8,074 All records2018: 8,349 All records2019: 8,745 All records2020: 9,730 All records2021: 10,571 All records2022: 11,744 All records2023: 11,240 All records2024: 11,144 All records2025: 10,577 All records20122013201420152016201720182019202020212022202320242025

Trials and syntheses per year

Drawn on their own scale; they are a small share of the total.

04509001,3501,8002012: 1,017 Reviews2013: 1,137 Reviews2014: 1,106 Reviews2015: 1,085 Reviews2016: 1,161 Reviews2017: 1,155 Reviews2018: 1,176 Reviews2019: 1,198 Reviews2020: 1,247 Reviews2021: 1,413 Reviews2022: 1,607 Reviews2023: 1,505 Reviews2024: 1,388 Reviews2025: 1,326 Reviews2012: 624 Randomised trials2013: 717 Randomised trials2014: 792 Randomised trials2015: 725 Randomised trials2016: 787 Randomised trials2017: 742 Randomised trials2018: 719 Randomised trials2019: 715 Randomised trials2020: 771 Randomised trials2021: 746 Randomised trials2022: 747 Randomised trials2023: 660 Randomised trials2024: 720 Randomised trials2025: 749 Randomised trials2012: 190 Meta-analyses2013: 224 Meta-analyses2014: 240 Meta-analyses2015: 235 Meta-analyses2016: 312 Meta-analyses2017: 269 Meta-analyses2018: 266 Meta-analyses2019: 329 Meta-analyses2020: 365 Meta-analyses2021: 453 Meta-analyses2022: 570 Meta-analyses2023: 491 Meta-analyses2024: 565 Meta-analyses2025: 523 Meta-analyses20122013201420152016201720182019202020212022202320242025
ReviewsRandomised trialsMeta-analyses
Substances studiedindexed substances
  1. Hypoglycemic Agents25,355 · steady
  2. Blood Glucose24,948 · steady
  3. Glycated Hemoglobin16,586 · steady
  4. Insulin13,483 · steady
  5. Biomarkers10,029 · steady
  6. Glucose6,616 · rising
  7. Sodium-Glucose Transporter 2 Inhibitors6,101 · rising
  8. hemoglobin A1c protein, human5,985 · falling
  9. Metformin5,949 · steady
  10. Dipeptidyl-Peptidase IV Inhibitors3,415 · steady
  11. Glucagon-Like Peptide 13,100 · rising
  12. Glucagon-Like Peptide-1 Receptor Agonists2,818 · rising
  13. Triglycerides2,752 · steady
  14. Glucosides2,617 · rising
Studied alongsideco-indexed subject headings
  1. Hypoglycemic Agents25,384
  2. Blood Glucose24,965
  3. Risk Factors22,103
  4. Glycated Hemoglobin16,599
  5. Obesity13,679
  6. Insulin13,494
  7. Insulin Resistance10,755
  8. Cardiovascular Diseases10,644
  9. Biomarkers10,037
  10. Body Mass Index7,156
  11. Glucose6,621
  12. Sodium-Glucose Transporter 2 Inhibitors6,112
  13. Metformin5,958
  14. Diabetic Nephropathies5,316
Where it is publishedjournals by record count
  1. Diabetes care3,025
  2. Diabetes, obesity & metabolism3,025
  3. PloS one2,683
  4. Diabetes research and clinical practice2,486
  5. Frontiers in endocrinology2,112
  6. Scientific reports1,921
  7. Diabetologia1,720
  8. Diabetic medicine : a journal of the British Diabetic Association1,657
  9. Cardiovascular diabetology1,509
  10. Nutrients1,450

Counts are research records carrying the subject heading, not a measure of research quality or spend. Randomised trials and meta-analyses are recorded study designs. Rising and falling compare records per year in 2012–2021 against 2022–2025, because the two windows are different lengths.

News attention

87,528 articles across five years matched this subject. News volume measures attention, not incidence or severity — it is included here because the gap between what is covered and what is supported is one of the things this report is for.

Prism news corpus

Matched coverage per month

87,528 articles, 2021-05 to 2026-05. The final month is drawn dashed: the most recent weeks are still being ingested and always read low.

08801,7602,6403,5202021-05: 736 matched articles2021-06: 903 matched articles2021-07: 821 matched articles2021-08: 816 matched articles2021-09: 895 matched articles2021-10: 814 matched articles2021-11: 934 matched articles2021-12: 871 matched articles2022-01: 2,616 matched articles2022-02: 883 matched articles2022-03: 995 matched articles2022-04: 861 matched articles2022-05: 928 matched articles2022-06: 1,001 matched articles2022-07: 896 matched articles2022-08: 969 matched articles2022-09: 1,081 matched articles2022-10: 975 matched articles2022-11: 1,182 matched articles2022-12: 1,140 matched articles2023-01: 2,874 matched articles2023-02: 997 matched articles2023-03: 1,274 matched articles2023-04: 1,019 matched articles2023-05: 1,127 matched articles2023-06: 1,454 matched articles2023-07: 1,066 matched articles2023-08: 1,162 matched articles2023-09: 1,178 matched articles2023-10: 1,292 matched articles2023-11: 1,373 matched articles2023-12: 1,215 matched articles2024-01: 2,669 matched articles2024-02: 1,783 matched articles2024-03: 2,776 matched articles2024-04: 2,485 matched articles2024-05: 2,075 matched articles2024-06: 1,313 matched articles2024-07: 1,335 matched articles2024-08: 1,312 matched articles2024-09: 1,307 matched articles2024-10: 1,330 matched articles2024-11: 1,500 matched articles2024-12: 1,450 matched articles2025-01: 3,143 matched articles2025-02: 1,597 matched articles2025-03: 1,778 matched articles2025-04: 1,444 matched articles2025-05: 1,566 matched articles2025-06: 1,519 matched articles2025-07: 1,887 matched articles2025-08: 1,828 matched articles2025-09: 1,967 matched articles2025-10: 1,751 matched articles2025-11: 1,854 matched articles2025-12: 1,937 matched articles2026-01: 2,079 matched articles2026-02: 1,626 matched articles2026-03: 1,893 matched articles2026-04: 1,976 matched articles2021-052021-112022-052022-112023-052023-112024-052024-112025-052025-112026-04

What changed between the last two years

Themes by share of coverage

Gaining share of coverage

Losing share

Change in each theme's share of matched coverage between 2024-05–2025-05 (19,584 articles) and 2025-05–2026-05 (21,883 articles). A share change is not a percentage-point change, and a theme can gain share while its raw count falls.

How the coverage reads

Sentiment of every matched article

25%17%30%14%
Very positive — 1,585 (1.0%)Positive — 39,362 (25.3%)Mildly positive — 26,511 (17.1%)Leaning positive — 46,394 (29.8%)Neutral — 7,599 (4.9%)Leaning negative — 22,052 (14.2%)Mildly negative — 5,481 (3.5%)Negative — 6,097 (3.9%)Very negative — 367 (0.2%)
Coverage by subcategorynews model labels
  1. diabetes medication management37,756
  2. chronic disease research (e.g., cancer, diabetes)19,554
  3. diabetes & heart disease interplay11,595
  4. glycemic index and diabetes nutrition2,933
  5. type 1 diabetes management2,714
  6. diabetes-friendly meal plans2,137
  7. exercise and physical activity for diabetics1,894
  8. pediatric diabetes care and monitoring1,873
  9. diabetes and obesity management1,858
  10. prediabetes intervention strategies1,763
  11. oral hypoglycemic agents for diabetes1,590
  12. diabetes epidemiology and population health1,506
Named most oftenorganisations in matched coverage
  1. novo nordisk1,011
  2. lilly539
  3. medtronic366
  4. tandem diabetes care235
  5. mayo clinic140
  6. american diabetes association140
  7. american heart association118
  8. sanofi113
  9. eli lilly and company94
  10. abbott93
  11. insulet87
  12. national institutes of health86

What people actually deal with

572,618 typed signals from 572,607 public conversations, covering 32,024 distinct treatments, devices and symptoms. The research record says what works; this says what living with it is like — what people ask, what they can afford, and what they stop taking.

Prism social signals

Signals per year and what they were doing

Every typed signal, and the kind of message it came from

031,12762,25593,382124,5092015: 16,506 signals2016: 19,144 signals2017: 21,572 signals2018: 28,114 signals2019: 31,271 signals2020: 29,984 signals2021: 40,457 signals2022: 57,017 signals2023: 82,470 signals2024: 111,169 signals2025: 104,983 signals20152016201720182019202020212022202320242025
  1. Mentioned in passing238,135
  2. Describing an experience111,804
  3. Recommending to someone81,475
  4. Asking for help42,505
  5. Discussing dose30,405
  6. Switching treatment22,712
  7. Warning others15,535
  8. Asking a question14,526

What the conversation is about

Share of signals by aspect

  1. Does it work126,806
  2. Fitting it into daily life117,780
  3. Dose and titration33,505
  4. How bad it is29,158
  5. How quickly it acts19,057
  6. Cost and access12,774
  7. Side effects6,475
  8. Supply and shortages5,381
  9. Device accuracy4,842
  10. Safety3,496

What people ask most

Recurring questions and requests for help, de-duplicated. Wording is as written, lightly tidied.

  1. Availability discussion for zepbound prescriptions170 times
  2. How much are you paying for ozempic?32 times
  3. Off-label weight loss not diabetes20 times
  4. How do you afford zepbound?19 times
  5. How are y'all getting and affording ozempic?19 times
  6. Insurance will deny it because not diabetic19 times
  7. Unable to get ozempic because of type 1 diabetes18 times
  8. Pharmacy filling prescription within business days due to limited refrigeration space18 times
  9. Insurance coverage for zepbound17 times
  10. CVS told me to give up on zepbound, that it's not being made right now16 times
  11. Insurance coverage for ozempic in canada for non diabetic15 times
  12. Post flair selection for zepbound prescription filling14 times

Treatments as people describe them

Positive share counts only signals the model judged either way; neutral mentions are excluded from it.

TreatmentMentionsOf those judgedSide-effect reportsCost & access
ozempic74,87666% positive
2,6693,087
metformin55,29558% positive
3,894140
insulin43,33345% positive
4271,312
zepbound31,60169% positive
1,1602,195
lantus10,93654% positive
272268
humalog6,83758% positive
38253
mounjaro6,65685% positive
114137
zep4,73679% positive
55373
novolog3,30359% positive
30139
wegovy3,03570% positive
39119

Devices as people describe them

Same measure, monitoring and delivery hardware

DeviceMentionsOf those judgedSide-effect reportsCost & access
dexcom28,42268% positive
8937
cgm8,87491% positive
0235
dexcom g68,02072% positive
3168
omnipod7,60678% positive
473
libre5,07871% positive
0156
insulin pump4,60177% positive
096
pump4,38183% positive
039
freestyle libre4,06681% positive
1114
dexcom g73,64049% positive
277
medtronic2,87249% positive
0119

These are lived-experience signals, not clinical evidence and not a representative survey: the people who post are not a sample of everyone with the condition, and a treatment discussed more is usually a treatment prescribed more. Read them next to the evidence graph, not instead of it.

Where it is written about

Three different geographies of the same subject: where the news reports it, which regions carry that coverage, and where the companies working on it are based. None of them measures where the disease actually is.

Prism geography

Where the news is written

87,528 matched articles · 59 countries with coverage

Zimbabwe: no matched coverage in this windowZambia: no matched coverage in this windowYemen: no matched coverage in this windowVietnam: no matched coverage in this windowVenezuela: no matched coverage in this windowVanuatu: no matched coverage in this windowUzbekistan: no matched coverage in this windowUruguay: no matched coverage in this windowGuam: no matched coverage in this windowPuerto Rico: no matched coverage in this windowUnited States of America: 10,660 matched articlesSouth Georgia and the Islands: no matched coverage in this windowFalkland Islands: no matched coverage in this windowIsle of Man: no matched coverage in this windowUnited Kingdom: 1,701 matched articlesUnited Arab Emirates: 75 matched articlesUkraine: 19 matched articlesUganda: no matched coverage in this windowTurkmenistan: 13 matched articlesTurkey: 57 matched articlesTunisia: no matched coverage in this windowTrinidad and Tobago: no matched coverage in this windowTogo: no matched coverage in this windowEast Timor: no matched coverage in this windowThailand: 24 matched articlesUnited Republic of Tanzania: no matched coverage in this windowTajikistan: no matched coverage in this windowTaiwan: 50 matched articlesSyria: no matched coverage in this windowSwitzerland: 123 matched articlesSweden: 189 matched articleseSwatini: no matched coverage in this windowSuriname: no matched coverage in this windowSouth Sudan: no matched coverage in this windowSudan: no matched coverage in this windowSri Lanka: 18 matched articlesSpain: 222 matched articlesSouth Korea: 105 matched articlesSouth Africa: 47 matched articlesSomalia: no matched coverage in this windowSomaliland: no matched coverage in this windowSolomon Islands: no matched coverage in this windowSlovakia: no matched coverage in this windowSlovenia: no matched coverage in this windowSierra Leone: no matched coverage in this windowRepublic of Serbia: no matched coverage in this windowSenegal: no matched coverage in this windowSaudi Arabia: 29 matched articlesSão Tomé and Principe: no matched coverage in this windowSamoa: no matched coverage in this windowRwanda: no matched coverage in this windowRussia: 13 matched articlesRomania: no matched coverage in this windowQatar: no matched coverage in this windowPortugal: 27 matched articlesPoland: 20 matched articlesPhilippines: 54 matched articlesPeru: no matched coverage in this windowParaguay: no matched coverage in this windowPapua New Guinea: no matched coverage in this windowPanama: 19 matched articlesPakistan: 29 matched articlesOman: 14 matched articlesNorway: 170 matched articlesNorth Korea: no matched coverage in this windowNigeria: 105 matched articlesNiger: no matched coverage in this windowNicaragua: no matched coverage in this windowNew Zealand: 140 matched articlesNetherlands: 20 matched articlesNepal: no matched coverage in this windowNamibia: no matched coverage in this windowMozambique: no matched coverage in this windowMorocco: no matched coverage in this windowWestern Sahara: no matched coverage in this windowMontenegro: no matched coverage in this windowMongolia: no matched coverage in this windowMoldova: no matched coverage in this windowMexico: 50 matched articlesMauritius: no matched coverage in this windowMauritania: no matched coverage in this windowMali: no matched coverage in this windowMalaysia: 33 matched articlesMalawi: no matched coverage in this windowMadagascar: no matched coverage in this windowNorth Macedonia: no matched coverage in this windowLuxembourg: no matched coverage in this windowLithuania: no matched coverage in this windowLibya: no matched coverage in this windowLiberia: no matched coverage in this windowLesotho: no matched coverage in this windowLebanon: no matched coverage in this windowLatvia: no matched coverage in this windowLaos: no matched coverage in this windowKyrgyzstan: no matched coverage in this windowKuwait: no matched coverage in this windowKosovo: no matched coverage in this windowKenya: 31 matched articlesKazakhstan: no matched coverage in this windowJordan: no matched coverage in this windowJapan: 163 matched articlesJamaica: 13 matched articlesItaly: 126 matched articlesIsrael: 48 matched articlesPalestine: no matched coverage in this windowIreland: 85 matched articlesIraq: no matched coverage in this windowIran: 34 matched articlesIndonesia: 41 matched articlesIndia: 2,474 matched articlesIceland: 17 matched articlesHungary: 14 matched articlesHonduras: no matched coverage in this windowHaiti: no matched coverage in this windowGuyana: no matched coverage in this windowGuinea-Bissau: no matched coverage in this windowGuinea: no matched coverage in this windowGuatemala: no matched coverage in this windowGreece: 17 matched articlesGhana: 55 matched articlesGermany: 312 matched articlesGeorgia: no matched coverage in this windowGambia: no matched coverage in this windowGabon: no matched coverage in this windowFrance: 189 matched articlesFrench Polynesia: no matched coverage in this windowNew Caledonia: no matched coverage in this windowFrench Southern and Antarctic Lands: no matched coverage in this windowAland: no matched coverage in this windowFinland: 37 matched articlesFiji: no matched coverage in this windowEthiopia: no matched coverage in this windowEstonia: no matched coverage in this windowEritrea: no matched coverage in this windowEquatorial Guinea: no matched coverage in this windowEl Salvador: no matched coverage in this windowEgypt: 29 matched articlesEcuador: no matched coverage in this windowDominican Republic: no matched coverage in this windowDominica: no matched coverage in this windowDjibouti: no matched coverage in this windowGreenland: no matched coverage in this windowFaroe Islands: no matched coverage in this windowDenmark: 171 matched articlesCzechia: no matched coverage in this windowNorthern Cyprus: no matched coverage in this windowCyprus: no matched coverage in this windowCuba: no matched coverage in this windowCroatia: no matched coverage in this windowIvory Coast: no matched coverage in this windowCosta Rica: no matched coverage in this windowDemocratic Republic of the Congo: no matched coverage in this windowRepublic of the Congo: 15 matched articlesComoros: no matched coverage in this windowColombia: 39 matched articlesChina: 578 matched articlesHong Kong S.A.R.: no matched coverage in this windowChile: 11 matched articlesChad: no matched coverage in this windowCentral African Republic: no matched coverage in this windowCabo Verde: no matched coverage in this windowCanada: 439 matched articlesCameroon: 12 matched articlesCambodia: no matched coverage in this windowMyanmar: no matched coverage in this windowBurundi: no matched coverage in this windowBurkina Faso: no matched coverage in this windowBulgaria: no matched coverage in this windowBrunei: no matched coverage in this windowBrazil: 140 matched articlesBotswana: no matched coverage in this windowBosnia and Herzegovina: no matched coverage in this windowBolivia: no matched coverage in this windowBhutan: no matched coverage in this windowBenin: no matched coverage in this windowBelize: no matched coverage in this windowBelgium: 82 matched articlesBelarus: no matched coverage in this windowBangladesh: 16 matched articlesBahrain: no matched coverage in this windowThe Bahamas: no matched coverage in this windowAzerbaijan: no matched coverage in this windowAustria: 81 matched articlesAustralia: 509 matched articlesHeard Island and McDonald Islands: no matched coverage in this windowArmenia: no matched coverage in this windowArgentina: no matched coverage in this windowAngola: no matched coverage in this windowAlgeria: no matched coverage in this windowAlbania: no matched coverage in this windowAfghanistan: no matched coverage in this windowSiachen Glacier: no matched coverage in this windowJersey: 14 matched articlesSingapore: 126 matched articles
LowerHigherGrey: no matched coverage

States and regions

Matched articles by reported region

State or regionCountryArticles
CaliforniaUnited States1,126
New YorkUnited States854
TexasUnited States568
MassachusettsUnited States456
EnglandChina438
FloridaUnited States436
OklahomaUnited States362
MaharashtraIndia345
IllinoisUnited States330
PennsylvaniaUnited States308
VikenNorway288
ArizonaUnited States274
DelhiIndia257
New JerseyUnited States245
WashingtonUnited States209
IndianaUnited States190
MarylandUnited States185
North CarolinaUnited States183
OhioIndia181
MichiganUnited States177

Where the companies are

One point per recorded headquarters

1,230 of 1,260 companies record a headquarters location.

City tags in the news corpus mix cities with states and acronyms, so this chapter uses country and state tags only. A country's article count reflects reported location and how much news that country produces; the relative-attention view divides that out.

What is being patented

49,718 patent publications between 2010 and 2024 name this subject in their title. Patents show where money expects a return, which is a different signal from either the research record or the news.

Prism patent corpus

Patent publications per year

49,718 publications on the strict match, 2010–2024.

01,7893,5785,3677,1562010: 3,861 Broad match2011: 4,630 Broad match2012: 4,164 Broad match2013: 4,276 Broad match2014: 4,580 Broad match2015: 4,790 Broad match2016: 4,829 Broad match2017: 4,682 Broad match2018: 4,822 Broad match2019: 4,979 Broad match2020: 5,221 Broad match2021: 6,389 Broad match2022: 5,802 Broad match2023: 5,500 Broad match2024: 5,775 Broad match2010: 2,757 Strict match2011: 3,477 Strict match2012: 2,877 Strict match2013: 2,975 Strict match2014: 3,172 Strict match2015: 3,205 Strict match2016: 3,183 Strict match2017: 3,207 Strict match2018: 3,225 Strict match2019: 3,352 Strict match2020: 3,306 Strict match2021: 3,991 Strict match2022: 3,647 Strict match2023: 3,573 Strict match2024: 3,771 Strict match201020112012201320142015201620172018201920202021202220232024
Broad matchStrict match

Which ideas are growing inside the filing record

Title-term matches. Change compares filings per year, because the two windows are six years and five.

Theme in the filing title2014–192020–24Per year
machine learning67815.6×
biosensor9253.3×
wound1504043.2×
insulin delivery1914002.5×
gene therapy29572.4×
artificial pancreas38732.3×
closed loop13242.2×
glucagon-like peptide2073331.9×
retinopathy2964721.9×
stem cell1682361.7×
neuropathy1932621.6×
continuous glucose40541.6×
Classification areasdistinct patents per CPC group
  1. A61K — Medicinal preparations26,866
  2. A61P — Therapeutic activity of compounds24,874
  3. C07K — Peptides7,227
  4. C07D — Heterocyclic compounds4,917
  5. A23L — Foods and non-alcoholic beverages4,216
  6. A23V — Food composition indexing4,140
  7. G01N — Investigating materials by analysis3,944
  8. G16H — Healthcare informatics3,006
  9. C12N — Micro-organisms, enzymes, genetic engineering2,907
  10. A61B — Diagnosis and surgery2,833
Named on the most filingsassignees as recorded
  1. NOVO NORDISK AS937
  2. KVASENKOV OLEG IVANOVICH748
  3. SANOFI AVENTIS DEUTSCHLAND644
  4. MERCK SHARP & DOHME612
  5. BOEHRINGER INGELHEIM INT597
  6. LILLY CO ELI558
  7. HOFFMANN LA ROCHE550
  8. HANMI PHARM IND CO LTD398
  9. SANOFI SA338
  10. PFIZER254
  11. ZEALAND PHARMA AS228
  12. JANSSEN PHARMACEUTICA NV218
Assignee countriesdistinct patents
  1. United States9,458
  2. South Korea2,963
  3. Germany1,963
  4. China1,555
  5. Russia1,286
  6. Denmark1,180
  7. Japan1,117
  8. France1,045
  9. Switzerland1,028
  10. United Kingdom646

Publication lags filing by roughly eighteen months, so the last years of this window are structurally incomplete and a fall at the right-hand edge is not a fall in activity. Assignee is whoever the filing names, which includes prolific individual inventors alongside companies.

What the companies are building

The 1,260 companies in this field are not building one thing. Grouping them by what they say they do separates the monitoring hardware from the drugs, the software from the surgery — and shows which approaches are the newer arrivals.

Prism company record
Drugs & therapeutics264 companies
$10,992M raised · 30 countries
  1. Intarcia$2,109M
    Provider of osmotic pump for subcutaneous drug delivery
  2. Kailera$1,000M
    Developer of therapies for treating obesity and related conditions
  3. Kriya Therapeutics$938M
    Developer of therapeutic solutions for the treatment of diabetes
Continuous glucose monitoring252 companies
$3,859M raised · 42 countries
  1. Dexcom$1,964M
    Provider of a wearable device for glucose monitoring
  2. Tandem Diabetes$508M
    Developer of devices for continuous glucose monitoring and manual insulin delivery
  3. Intuity Medical$309M
    All-in-one blood glucose monitoring system
Non-invasive measurement100 companies
$354M raised · 28 countries
  1. Know Labs$63M
    Developer of non-invasive technology for identifying and measuring molecules
  2. Indigo$55M
    Needle free glucose monitoring technology
  3. RSP Systems$35M
    Provider of a non-invasive blood glucose monitoring device
Diagnostics & testing98 companies
$145M raised · 23 countries
  1. Laxmi Therapeutic Devices$24M
    Develper of a wearable diagnostic device for continuous glucose monitoring
  2. Bluedrop Medical$19M
    Developer of diagnostic technology for diabetes -related complications
  3. Mellitus$18M
    In vitro diagnostic test for Gestational Diabetes Mellitus (GDM)
Foot & wound care86 companies
$433M raised · 18 countries
  1. Podimetrics$103M
    Provider of diabetic foot ulcer monitoring device for patients and doctors
  2. Trice Medical$94M
    Minimally invasive solutions for orthopedic and podiatric procedures, improving patient outcomes
  3. Reapplix$52M
    Developer of patch system for wound healing
Wearables64 companies
$3,724M raised · 23 countries
  1. Dexcom$1,964M
    Provider of a wearable device for glucose monitoring
  2. CeQur$392M
    Developer of wearable insulin delivery patch
  3. Insulet$381M
    Manufacturer of wearable, tubeless insulin delivery systems for diabetes management
Insulin delivery54 companies
$2,118M raised · 16 countries
  1. Tandem Diabetes$508M
    Developer of devices for continuous glucose monitoring and manual insulin delivery
  2. CeQur$392M
    Developer of wearable insulin delivery patch
  3. Insulet$381M
    Manufacturer of wearable, tubeless insulin delivery systems for diabetes management
Cell & gene therapy34 companies
$422M raised · 11 countries
  1. Caladrius Biosciences$128M
    Developer of cell therapy based drugs for coronary microvascular dysfunction, diabetes, cancer a
  2. Regenxbio$127M
    Developer of AAV Gene Therapy for rare genetic diseases
  3. Elevian$61M
    Developer of regenerative therapies for treating age-related diseases
Digital care & coaching23 companies
$23M raised · 11 countries
  1. Kannact$14M
    Human-driven digital health company providing personalized support for chronic condition managem
  2. MedicSen$6M
    Mobile app to manage diabetes
  3. HELLO INSIDE$2M
    Provider of continuous glucose monitoring sensors and related mobile application

Which approaches are newer, and where the money moved

Cohort compares a theme's share of companies founded from 2017 against the field as a whole. Funding compares dollars per year in 2021–2026 against 2015–2020.

ThemeCompaniesFounded ≤2016Founded ≥2017CohortFunding per year
AI & analytics15311newer2.3×
Wearables643226newer0.3×
Digital care & coaching23129typical1.1×
Nutrition & lifestyle1475typical2.9×
Drugs & therapeutics26413795typical1.2×
Cell & gene therapy341610typical0.4×
Foot & wound care864427typical0.6×
Continuous glucose monitoring25213577typical0.1×
Non-invasive measurement1005932typical0.8×
Eye screening22126typical3.8×
Insulin delivery543013older0.4×
Kidney & organ complications752older0.5×
Diagnostics & testing985620older1.3×

Themes are read from each company's own description of itself, over the 1,199 of 1,260 companies that carry one. A company can sit in more than one theme, so the counts do not sum to the total. Funding counts rounds that state an amount.

Companies & capital

1,260 companies are classified to this field, 417 of them with a funding round on record. This is the commercial edge of the same subject the research and patent chapters describe.

Prism company record
1,260companies classified to this field
417with at least one recorded funding round
1,755funding rounds on record
$22.9Bdisclosed across rounds that state an amount

Companies founded per year

By recorded founding year. Recent years are incomplete: a company enters the record once it is covered, not when it is formed.

02652771032000: 17 companies founded2001: 14 companies founded2002: 17 companies founded2003: 30 companies founded2004: 21 companies founded2005: 27 companies founded2006: 35 companies founded2007: 27 companies founded2008: 29 companies founded2009: 47 companies founded2010: 54 companies founded2011: 49 companies founded2012: 46 companies founded2013: 58 companies founded2014: 61 companies founded2015: 75 companies founded2016: 71 companies founded2017: 77 companies founded2018: 62 companies founded2019: 92 companies founded2020: 45 companies founded2021: 39 companies founded2022: 27 companies founded2023: 15 companies founded2024: 5 companies founded2000200220042006200820102012201420162018202020222024

Disclosed funding per year

Rounds that state an amount

$0.0B$1.1B$2.2B$3.3B$4.4B2010: $0.6B raised2011: $0.6B raised2012: $0.7B raised2013: $0.6B raised2014: $1.0B raised2015: $1.0B raised2016: $1.4B raised2017: $1.5B raised2018: $1.6B raised2019: $0.8B raised2020: $3.9B raised2021: $1.8B raised2022: $1.5B raised2023: $1.0B raised2024: $1.1B raised2025: $1.5B raised2026: $0.5B raised20102011201220132014201520162017201820192020202120222023202420252026

Best-funded companies in this field

Ranked by disclosed equity across 1,755 rounds.

CompanyHQFoundedRoundsDisclosed
IntarciaProvider of osmotic pump for subcutaneous drug deliveryBoston, United States199522$2,109M
DexcomProvider of a wearable device for glucose monitoringSan Diego, United States19998$1,964M
KaileraDeveloper of therapies for treating obesity and related conditionsWaltham, United States20242$1,000M
Kriya TherapeuticsDeveloper of therapeutic solutions for the treatment of diabetesRedwood City, United States20125$938M
Sana BiotechnologyDeveloper of engineered cell therapies for treating various human diseasesSeattle, United States20181$821M
LivongoProvider of smart devices for diabetes management for patients and doctorsSan Francisco, United States20148$720M
Tandem DiabetesDeveloper of devices for continuous glucose monitoring and manual insulin deliverySan Diego, United States20086$508M
OnduoDiabetes monitoring and management systemsNewton, United States20161$500M
CeQurDeveloper of wearable insulin delivery patchHorw, Switzerland20085$392M
CarmotDeveloper of disease-modifying therapies to treat metabolic diseasesBerkeley, United States200816$391M
InsuletManufacturer of wearable, tubeless insulin delivery systems for diabetes managementBoston, United States20008$381M
Lexicon PharmaceuticalsDeveloper of small molecule drugs for diffrent health diseasesThe Woodlands, United States199511$381M
Apollo TherapeuticsDeveloper of therapeutic programs based on biological and medical researchCambridge, United Kingdom20202$372M
ValeritasDeveloper of wearable insulin patch pumps for insulin delivery through the skinBridgewater, United States20036$357M
Beta BionicsInnovating diabetes management with automated bionic pancreas technologyBoston, United States201510$351M
Rounds by stageas named on the round
  1. Grant (prize money)400
  2. Seed317
  3. Post IPO290
  4. Series A284
  5. Series B162
  6. Series C88
  7. Conventional Debt81
  8. Series D39
  9. PE19
  10. Unattributed17
Company stagelifecycle as recorded
  1. Unfunded325
  2. Deadpooled295
  3. Funding Raised119
  4. Acquired88
  5. Seed88
  6. Public75
  7. Series A69
  8. Not recorded64
  9. Private41
  10. Series B40
Also classified asother sector feeds on the same companies
  1. Medical Devices628
  2. Diabetes Devices608
  3. Chronic Disease Management473
  4. Glucose Monitoring Devices447
  5. At Home Diagnostics440
  6. Life Sciences - US429
  7. Non Invasive Diabetes Monitoring332
  8. IoT in Healthcare325
  9. Biopharmaceuticals302
  10. Diabetes Drugs299
  11. Enterprise Tech - US286
  12. Non-Invasive Health Monitoring Devices275

The record carries an amount for only some rounds, so the disclosed total is a floor, not a market size. Companies are included by their recorded sector classification, which is coarser than the condition itself.

What the businesses actually earn

Funding is what a company raised; this is what it earned. 22 companies in this field file annual accounts in India, giving real multi-year revenue, profit and margin — including the loss-making years.

Official filings

Indian operations: filed accounts

22 legal entities with at least two filed years, from 50 companies in this field based in India. 7 were profitable in their latest filed year; 9 grew revenue across the period. Figures in rupee crore, as filed.

CompanyRevenue trendLatest revenueNet marginRevenue CAGR
India Medtronic Private Limited5 filed years · FY2021–FY2025₹2,638.9 cr+5.2%+22.9%
Haiden Technology Private Limited5 filed years · FY2021–FY2025₹66.3 cr+2.5%+11.3%
Levim Lifetech Private Limited5 filed years · FY2021–FY2025₹30.6 cr+0.8%—
Kriya Medical Technologies Private Limited5 filed years · FY2021–FY2025₹20.7 cr-88.3%+18.9%
Biosense Technologies Private Limited5 filed years · FY2021–FY2025₹16.6 cr+1.2%-36.1%
Elicad Pharmaceuticals Private Limited5 filed years · FY2021–FY2025₹9.7 cr+4.8%—
Sekkei Bio Private Limited5 filed years · FY2021–FY2025₹7.2 cr-27.3%—
Diabetik Foot Care India Private Limited5 filed years · FY2021–FY2025₹6.5 cr+3.4%+24.3%
Biogenomics Limited5 filed years · FY2019–FY2023₹5.1 cr-602.5%-24.1%
Ayati Devices Private Limited5 filed years · FY2021–FY2025₹4.0 cr+8.6%+347.2%
Yostra Labs Private Limited5 filed years · FY2021–FY2025₹2.6 cr-22.1%+48.1%
Genesis Medical Systems Private Limited5 filed years · FY2021–FY2025₹1.4 cr-0.3%+41.7%

The same view, United States

Held back on this page. The coverage below is real and the companies are named; the figures open in Radar.

506US companies in this field
181with revenue on record
221with headcount on record
43with a public filing history
CompanyRevenueMarginHeadcountOn file
MiniMedNorthridge, United States · listed•••••••••••—
DexcomSan Diego, United States · listed•••••••••••✓
FiaspPlainsboro, United States•••••••••••—
InsuletBoston, United States · listed•••••••••••✓
Capillary BiomedicalIrvine, United States•••••••••••—
Tandem DiabetesSan Diego, United States · listed•••••••••••✓
EmbectaParsippany, United States · listed•••••••••••✓
Medtronic DiabetesNorthridge, United States•••••••••••—
VivaChekWilmington, United States•••••••••••✓
AnimasUnited States•••••••••••—
DisetronicIndianapolis, United States•••••••••••—
RegenxbioRockville, United States · listed•••••••••••✓
Revenue, margin and headcount for these companies are on file.Filed and estimated figures, multi-year where available, alongside funding and hiring.
Open in Radar

Indian figures are statutory company accounts as filed, keyed to the registered legal entity rather than to a brand name — one brand can file under several entities, and a subsidiary of a foreign parent files here like any other domestic company. Net margin is profit after tax over revenue from operations. Loss-making years are shown as filed, not hidden.

What people install

759 apps name this subject in their title, with 149 million installs between them. It is the cheapest thing anyone builds around a health subject, and the quality spread shows it.

Radar app signals
759apps naming the condition in the title
149Minstalls across them
4.0mean rating, of the 158 rated
739free to install

Apps released per year

By recorded release date

02855831112012: 5 apps released2013: 9 apps released2014: 7 apps released2015: 9 apps released2016: 20 apps released2017: 18 apps released2018: 25 apps released2019: 24 apps released2020: 35 apps released2021: 26 apps released2022: 47 apps released2023: 65 apps released2024: 71 apps released2025: 99 apps released20122013201420152016201720182019202020212022202320242025

How they are rated

158 of 759 carry a rating

20%40%32%8%
4.5 and above — 31 (19.6%)4.0–4.5 — 63 (39.9%)3.0–4.0 — 51 (32.3%)below 3.0 — 13 (8.2%)

Most installed

Apps with more than 400 ratings, so a single review cannot place one here

AppInstallsRatingRatingsCategoryReleased
Blood Sugar - Diabetes AppQR Code Scanner.22,229,3134.550,595Health & Fitness2022
Blood Sugar & Diabetes TrackerPidomTech19,376,8283.612,452Health & Fitness2025
Dr. Blood Pressure: DiabetesHealthy Care Technology AI Lab7,785,3183.98,510Medical2022
Blood pressure - Blood Sugarhighsecure7,145,5793.915,334Health & Fitness2024
mySugr - Diabetes Tracker LogmySugr GmbH6,571,1734.5136,314Medical2013
Blood Sugar Diary for DiabetesCards6,430,9834.423,652Medical2020
Diabetes – Blood SugarBlood Sugar app5,269,1194.163,386Food & Drink2018
BeatO: Diabetes Care AppBeatO2,579,1964.345,316Health & Fitness2015
Blood Sugar&Pressure: iCardioCodeJoy2,484,9424.36,934Health & Fitness2025
Blood Sugar & Pressure TrackerHangzhou Suoyi Network Technology Co., Ltd.2,407,5024.416,431Health & Fitness2024
Health2Sync - Diabetes TrackerH2 Inc.2,240,3354.420,246Medical2014
Blood Sugar Tracker - DiabetesLeap Fitness Group1,810,2924.512,790Health & Fitness2021
Blood Sugar Care AppNova Xponential Power1,475,5383.3664Health & Fitness2026
Blood Sugar Care & BP MonitorWeather 365 Days1,237,8244.39,531Health & Fitness2024
By categoryapps, with installs behind them
  1. Health & Fitness352 · 106M installs
  2. Medical212 · 34M installs
  3. Food & Drink43 · 6M installs
  4. Personalization40 · 0M installs
  5. Education32 · 0M installs
  6. Tools30 · 2M installs
  7. Lifestyle19 · 0M installs
  8. Shopping7 · 0M installs

A marketplace listing is not a medical device and an install is not a user. Most of these apps are trackers rather than regulated products, and only 158 of 759 carry enough ratings to mean anything — the long tail is near-identical clones of the same tracker.

Full records

The complete tables behind the chapters above, including the rows that did not fit a ranking.

Inspect
News coverage by country59 countries
CountryArticlesShareRelative attentionCompaniesResearch
United States of America10,66012.18%0.46×50643,778
India2,4742.83%0.43×50—
United Kingdom1,7011.94%0.61×8335,507
China5780.66%0.54×651,790
Australia5090.58%0.50×171,793
Canada4390.50%0.47×461,392
Germany3120.36%0.64×376,999
Spain2220.25%0.45×91,114
Sweden1890.22%below threshold16—
France1890.22%below threshold281,770
Denmark1710.19%below threshold15—
Norway1700.19%below threshold8—
Japan1630.19%below threshold92,724
Brazil1400.16%below threshold——
New Zealand1400.16%below threshold——
Singapore1260.14%below threshold9—
Italy1260.14%below threshold121,142
Switzerland1230.14%below threshold258,911
Nigeria1050.12%below threshold——
South Korea1050.12%below threshold41—
Ireland850.10%below threshold—3,630
Belgium820.09%below threshold——
Austria810.09%below threshold7—
United Arab Emirates750.09%below threshold—1,345
Turkey570.07%below threshold8—
Ghana550.06%below threshold——
Philippines540.06%below threshold12—
Taiwan500.06%below threshold19—
Mexico500.06%below threshold——
Israel480.06%below threshold48—
South Africa470.05%below threshold——
Indonesia410.05%below threshold——
Colombia390.04%below threshold——
Finland370.04%below threshold——
Iran340.04%below threshold——
Malaysia330.04%below threshold——
Kenya310.03%below threshold——
Egypt290.03%below threshold——
Pakistan290.03%below threshold——
Saudi Arabia290.03%below threshold——
Portugal270.03%below threshold——
Thailand240.03%below threshold——
Netherlands200.02%below threshold196,827
Poland200.02%below threshold7—
Ukraine190.02%below threshold——
Panama190.02%below threshold——
Sri Lanka180.02%below threshold——
Greece170.02%below threshold——
Iceland170.02%below threshold——
Bangladesh160.02%below threshold——
Republic of the Congo150.02%below threshold——
Oman140.02%below threshold——
Jersey140.02%below threshold——
Hungary140.02%below threshold——
Russia130.01%below threshold——
Jamaica130.01%below threshold——
Turkmenistan130.01%below threshold——
Cameroon120.01%below threshold——
Chile110.01%below threshold——
News subcategories in full36 labels
SubcategoryArticlesPrior yearRecent year
diabetes medication management37,7568,4739,181
chronic disease research (e.g., cancer, diabetes)19,5544,2784,963
diabetes & heart disease interplay11,5952,3852,650
glycemic index and diabetes nutrition2,933636747
type 1 diabetes management2,714767703
diabetes-friendly meal plans2,137445580
exercise and physical activity for diabetics1,894381525
pediatric diabetes care and monitoring1,873370543
diabetes and obesity management1,858443648
prediabetes intervention strategies1,763321510
oral hypoglycemic agents for diabetes1,590346553
diabetes epidemiology and population health1,506308408
artificial pancreas systems and advanced diabetes technology1,354359294
diabetes risk factor assessment tools1,264247386
diabetic neuropathy prevention and care1,239273236
neurological complications of diabetes1,211309290
type 2 diabetes management1,099213428
diabetic retinopathy screening and treatment1,041231236
diabetic nephropathy risk and management1,013277220
diabetes and chronic kidney disease (ckd)913250233
diabetic skin conditions and care870213145
peripheral artery disease in diabetic patients852179154
endocrinology & diabetes treatment centers840210256
diabetes foot ulcer prevention and care836194149
diabetic-friendly footwear809284277
diabetes-related mental health support790181159
gestational diabetes monitoring and care786191173
elderly diabetes management702153157
diabetic ketoacidosis (dka) treatment protocols570147121
diabetes and cardiovascular complication prevention55999177
pediatric endocrine disorders and diabetes52395152
hyperglycemia management in diabetes46980159
bariatric surgery impact on diabetes outcomes408101114
dental and oral health in diabetes3457780
diabetes self-management education (dsme)2464181
gestational diabetes management2024952
Patent assignees in full25 names
AssigneePatentsSince 2020
NOVO NORDISK AS937370
KVASENKOV OLEG IVANOVICH7480
SANOFI AVENTIS DEUTSCHLAND64481
MERCK SHARP & DOHME61280
BOEHRINGER INGELHEIM INT597149
LILLY CO ELI558232
HOFFMANN LA ROCHE55058
HANMI PHARM IND CO LTD398240
SANOFI SA33871
PFIZER254163
ZEALAND PHARMA AS22889
JANSSEN PHARMACEUTICA NV21858
MERCK PATENT GMBH2140
DEXCOM INC200157
MEDIMMUNE LTD194101
UNIV CALIFORNIA17945
ASTRAZENECA AB17953
AMGEN INC16659
UNIV INDIANA RES & TECH CORP16317
BEIJING LVYUANQIUZHENG TECHNOLOGY DEV CO LTD1390
NOVARTIS AG1244
INST NAT SANTE RECH MED11868
ROCHE DIAGNOSTICS GMBH1182
UNIV VIRGINIA PATENT FOUNDATION11776
CAREGEN CO LTD11672
Substances in the research record30 indexed
SubstanceRecordsBefore 20222022 onward
Hypoglycemic Agents25,35517,0698,286
Blood Glucose24,94817,5207,428
Glycated Hemoglobin16,58611,2555,331
Insulin13,4839,5293,954
Biomarkers10,0297,2732,756
Glucose6,6163,1933,423
Sodium-Glucose Transporter 2 Inhibitors6,1012,7573,344
hemoglobin A1c protein, human5,9855,084901
Metformin5,9494,0921,857
Dipeptidyl-Peptidase IV Inhibitors3,4152,3841,031
Glucagon-Like Peptide 13,1001,7971,303
Glucagon-Like Peptide-1 Receptor Agonists2,8188961,922
Triglycerides2,7521,898854
Glucosides2,6171,5861,031
Lipids2,4851,778707
Benzhydryl Compounds2,3751,388987
Glucagon-Like Peptide-1 Receptor1,614980634
Sulfonylurea Compounds1,5811,232349
Cholesterol, LDL1,4351,005430
Cholesterol1,404978426
Liraglutide1,399989410
MicroRNAs1,346808538
Cholesterol, HDL1,345983362
Antioxidants1,330883447
Glucagon-Like Peptides1,308497811
C-Reactive Protein1,279967312
Plant Extracts1,275871404
Incretins1,263924339
Peptides1,229929300
empagliflozin1,195677518
Company locations30 cities
CityCountryCompanies
San DiegoUnited States32
San FranciscoUnited States21
BostonUnited States20
LondonUnited Kingdom18
New York CityUnited States17
SeoulSouth Korea12
ManilaPhilippines11
CambridgeUnited States11
ParisFrance9
SingaporeSingapore9
BengaluruIndia9
TaipeiTaiwan8
Tel AvivIsrael8
ChennaiIndia7
Palo AltoUnited States7
Hong KongChina7
Los AngelesUnited States7
TorontoCanada7
VancouverCanada6
MontrealCanada6
HangzhouChina6
CambridgeUnited Kingdom6
BeijingChina6
ShanghaiChina6
IrvineUnited States6
StockholmSweden5
AhmedabadIndia5
ZurichSwitzerland5
Seongnam-siSouth Korea5
DelhiIndia5

Sources & methods

Every window, every corpus and every limit that shapes a figure above.

Method
What this report is
One subject seen through five separate corpora. Nothing here is a clinical guideline, a diagnosis or a treatment recommendation. Where two corpora disagree, both are shown.
Scope
The evidence graph and the research chapter are scoped to type 2 diabetes specifically. The news, patent and company chapters are scoped to diabetes as a whole, because those three corpora rarely separate the types; where a figure covers all diabetes it says so.
The claim record
182,350 statements extracted from 122,065 research and news documents, each carrying a relation, a direction, a study design and a GRADE-style evidence strength. "High-strength" means high or very high. It describes the design behind a claim, not whether the claim is correct.
Research
Indexed research records carrying the subject heading, 2012–2025. Study design is as recorded on each record.
News
87,528 articles matched by the news model's subcategory labels, May 2021–Apr 2026, from the Prism news corpus. Ingest does not stop cleanly, it tails off: weekly volume through May 2026 runs 720k, 750k, 446k then 348k, and June holds about a fifth of a normal month. The window therefore ends with the last month that is whole, and the final point on the monthly chart is drawn dashed because even it is still filling in.
Patents
Publications 2010–2024 whose title matches the subject terms. Publication lags filing by roughly eighteen months.
Companies
1,260 companies from the Prism company record carrying the Diabetes sector classification, joined to 1,755 funding rounds. Amounts are disclosed values only; the record's own total-funding field is unpopulated for all but a handful of these companies and is not used.
Community voice
572,618 typed signals drawn from public patient and carer conversations through Prism social signals, each carrying what the message was doing (asking, recommending, reporting a side effect), a polarity and an aspect. Not a survey and not evidence: the people who post are not a sample of everyone with the condition. Wording is as written, lightly tidied; no individual, forum or platform is identified.
What is being built
Themes are keyword sets over each company's own description of itself, across the 1,199 companies that carry one. A company can sit in several themes, so the counts do not sum to the total.
Filed accounts
Statutory annual accounts as filed, keyed to the registered legal entity rather than to a brand: one brand can file under several entities. Figures in rupee crore. Net margin is profit after tax over revenue from operations. EBITDA is not derived here because it is meaningless for lenders and several of these entities are not manufacturers. The United States view is withheld on this page, not absent; its coverage counts are stated as they are.
App marketplace
759 listings whose title names the condition, with install counts and ratings as published by the marketplace. An install is not a user and a listing is not a regulated device.
What is not merged
Terms that mean the same thing in different words are not merged in the claim record, so a subject's totals can be split across spellings. The explorer states the same limit.